Enterprise AI & Agent Orchestration · Assurance Record
Hippocratic Agent Library
Hippocratic AI · Patient home / outreach · API/SaaS
Decision summary
- Suitable for
- Health systems, pharma R&D (expanding)
- Documentary gate
- Failed
- Scenario match
- No evaluated buying scenario currently covers this product
- Comparability
- Not yet comparable in this scenario
- Decision readiness
- HISTORICAL — Research only
- Documented evidence
- 0 of 1 evidence claims independently confirmed · confidence Low
- Critical unknowns
- scaled production deployment · documented economic outcomes
- Last independent review
- not yet measured
independent reportAcquired Grove to expand into pharma/medtech R&D agent workflows (CB Insights Q1'26).2026-04-15
Exact claim. Acquired Grove to expand into pharma/medtech R&D agent workflows (CB Insights Q1'26).
- Source
- cbinsights.com
- Type
- independent report
- Published
- 2026-04-15
- Retrieved
- 2026-08-27
- Verification
- unverified
- Confidence
- not stated
- Reviewer
- healthit-gate-v1
- Claim version
- v1
- Supports
- general
Independent source. Methodology and sample vary by report; read the underlying method.
Open cbinsights.comVerified provider experience is not yet publishable. Fewer than five independent provider organizations have contributed eligible reviews. Reviewer mode is off. Experience never changes documentary scoring, freshness, or rank.
Buyer lenses — evidence-backed bands (not a 0–100 rank)
Deployment, integration, data handling
- Integration maturity
- announced — Announced or documented integration; marketplace listing not confirmed.
- EHR path
- Integration via partner APIs (early)
- FHIR / API
- UNKNOWN
Why unknown
Why. No reliable source on file. The platform does not infer values from weak sources.
What would close it. A primary source or independent verification.
- SSO
- UNKNOWN
Why unknown
Why. Single-sign-on support is not documented in vendor or marketplace materials on file.
What would close it. Vendor security documentation or marketplace listing mentioning SSO/SAML/OIDC.
- PHI / BAA
- BAA; non-clinical scope by contract · BAA available
- Security attestations
- SOC 2 Type II
- FDA status
- UNKNOWN
Why unknown
Why. No FDA listing found for this product's functions in the tracked category.
What would close it. An FDA 510(k)/De Novo listing, or a clear statement that no regulated function is claimed.
- Pricing
- Reported ~$5/hr usage band early on; evolving
Technical provenance
snap_8a8a4c9bb810aee3 · 2026-08-27T04:05Z · build 6a9fe1b
Forecast calibration is not in the public snapshot — shown as UNKNOWN rather than read from SQLite.
Known limitations
- Deployment traction is UNKNOWN.
Why unknown
Why. No reliable source on file. The platform does not infer values from weak sources.
What would close it. A primary source or independent verification.
- Economic value evidence is UNKNOWN.
Why unknown
Why. No independently verifiable ROI claim (peer-reviewed, audited case, or independent benchmark) is on file.
What would close it. An audited implementation report or peer-reviewed study with payback/throughput numbers.